### CONTENTS MAY 2014

#### IN THIS ISSUE
Highlighted research articles .......................... 495

#### NEWS IN BRIEF
Important news stories affecting the community .................. 500

#### NEWS IN DEPTH
- Q&A: Mikala Egeblad on Tumor Microenvironment .............. 503
- Tracking CTCs May Improve Cancer Treatment ............... 504

#### RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature .................. 505

#### ONLINE
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

#### VIEWS
- **In The Spotlight**
  - Finding the Right Balance of BRAF Inhibition in Melanoma ....... 510
    M.A. Davies
    See article, p. 538
  - **MTOR Mutations in the Crosshairs of Targeted Therapy** ........ 513
    P.A. Rejto and R.T. Abraham
    See article, p. 546
    See article, p. 554
  - From Breaking Bad to Worse: Exploiting Homologous DNA Repair Deficiency in Cancer ........... 516
    M.T. Hemann
    See article, p. 592
  - Paths of Resistance to EGFR Inhibitors: Is NF Enough? ...... 519
    O. Maertens and K. Cickowski
    See article, p. 606

- **In Focus**
  - T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy .................. 522
    I. Melero, A. Rouzaut, G.T. Motz, and G. Coukos

#### REVIEW
Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy ...... 527

#### RESEARCH BRIEFS
- Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies ...... 538

  **Précis:** Intermittent combined use of the RAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in a patient with BRAF-mutant melanoma and NRAS-mutant leukemia controlled both diseases.
  See commentary, p. 510

- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib ...... 546

  **Précis:** The identification of two activating MTOR mutations in a patient who experienced a complete response to everolimus and pazopanib suggests an underlying mechanism of mTOR inhibitor sensitivity.
  See commentary, p. 513

- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity ........... 554

  **Précis:** Activating MTOR mutations are widespread in human cancers and correlate with hypersensitivity to mTOR pathway inhibition.
  See commentary, p. 513

---

Copyright © 2014 American Association for Cancer Research. Cancer Discovery online at cancerdiscovery.aacrjournals.org.
Vemurafenib treatment was previously shown to uncover an NRAS-mutant chronic myelomonocytic leukemia (CMML) in a patient with BRAF-mutant metastatic melanoma. Abdel-Wahab and colleagues report that the combination of vemurafenib and the MEK inhibitor cobimetinib blocked vemurafenib-induced CMML proliferation and restored normal white blood cell counts in this patient. Intermittent administration of vemurafenib and cobimetinib has durably maintained a near-complete melanoma response and has prevented CMML progression in association with decreased levels of CMML-derived circulating tumor DNA and reduced ERK activation in monocytes. Intermittent combination RAF and MEK inhibitor therapy may thus be useful for treatment of RAS-driven malignancies arising due to paradoxical activation of wild-type RAF by RAF inhibitors in RAS-mutant cells. For details, please see the article by Abdel-Wahab and colleagues on page 538.